Top

Published in:

Open Access 01-12-2021 | Ultrasound | Research article

Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan

Authors: Shin-ya Kawashiri, Yushiro Endo, Ayako Nishino, Momoko Okamoto, Sosuke Tsuji, Ayuko Takatani, Toshimasa Shimizu, Remi Sumiyoshi, Tomohiro Koga, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Hideki Nakamura, Tomoki Origuchi, Toshiyuki Aramaki, Yukitaka Ueki, Tamami Yoshitama, Nobutaka Eiraku, Naoki Matsuoka, Akitomo Okada, Keita Fujikawa, Hiroaki Hamada, Shuji Nagano, Yoshifumi Tada, Atsushi Kawakami

Published in: BMC Musculoskeletal Disorders | Issue 1/2021

Abstract

Background

To evaluate the effect of treatment on serum bone biomarkers and explore whether serum bone biomarkers are associated with therapeutic response in rheumatoid arthritis (RA) patients treated with abatacept.

Methods

We enrolled 59 RA patients treated with abatacept from a multicenter, exploratory, short-term, prospective and observational ultrasound cohort study of patients who received biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) therapy. We evaluated the patients’ clinical disease activity and musculoskeletal ultrasound (MSUS) scores. The serum concentrations of five bone biomarkers were evaluated (dickkopf-1 [Dkk-1], sclerostin [SOST], osteocalcin [OC], osteopontin [OPN], and osteoprotegerin [OPG]) by multiplex bead assays at baseline, 3, and 6 months: the change over 6 months was defined as the Δ value. ‘Power Doppler (PD) responder’ was defined as a patient whose Δtotal PD score over 6 months was greater than the median change.

Results

Abatacept significantly improved the clinical disease activity and MSUS score over 6 months. Serum OPG was significantly elevated at 6 months after the abatacept introduction (p = 0.016). The ΔSOST and ΔOPG were significantly greater in the PD responders versus the non-PD responders (p = 0.0041 and 0.0073, respectively). The serum Dkk-1 at baseline was significantly lower in the PD responders (n = 30) vs. the non-PD responders (n = 29) (p = 0.026). A multivariate logistic regression analysis showed that the serum Dkk-1 at baseline (odds ratio 0.50, 95% confidence interval [CI] 0.23–0.91, p = 0.043) was an independent predictor of PD responder status.

Conclusion

Serum levels of bone biomarkers may be useful for predicting RA patients’ therapeutic responses to abatacept.

Trial registration

Name of the registry: Assessment of therapeutic responsiveness by imaging of the joints in patients with rheumatoid arthritis; A observational cohort study

Trial registration number: UMIN000012524

Date of registration: 12/9/2013

URL of trial registry record: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000014657

Available only for authorised users

Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094–108. https://doi.org/10.1016/S0140-6736(10)60826-4.CrossRefPubMed

Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15. https://doi.org/10.1136/annrheumdis-2015-207524.CrossRefPubMed

Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002;46(6):1470–9. https://doi.org/10.1002/art.10294.CrossRefPubMed

Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barré E, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74(1):19–26. https://doi.org/10.1136/annrheumdis-2014-206106.CrossRefPubMed

Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73(1):86–94. https://doi.org/10.1136/annrheumdis-2013-203843.CrossRefPubMed

Kremer JM, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Westhovens R, et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis. 2011;70(10):1826–30. https://doi.org/10.1136/ard.2010.139345.CrossRefPubMed

Bathon J, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis. 2011;70(11):1949–56. https://doi.org/10.1136/ard.2010.145268.CrossRefPubMed

Matsubara T, Inoue H, Nakajima T, Tanimura K, Sagawa A, Sato Y, et al. Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study. RMD Open. 2018;4(2):e000813. https://doi.org/10.1136/rmdopen-2018-000813.CrossRefPubMedPubMedCentral

Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–99. https://doi.org/10.1136/annrheumdis-2019-216655.CrossRefPubMed

10.

Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J, et al. CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis. 2008;67(11):1603–9. https://doi.org/10.1136/ard.2007.080713.CrossRefPubMed

11.

Bozec A, Zaiss MM, Kagwiria R, Voll R, Rauh M, Chen Z, et al. T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway. Sci Transl Med. 2014;6:235ra60.CrossRefPubMed

12.

Fardellone P, Séjourné A, Paccou J, Goëb V. Bone remodelling markers in rheumatoid arthritis. Mediat Inflamm. 2014;2014:484280.CrossRef

13.

Komatsu N, Takayanagi H. Immune-bone interplay in the structural damage in rheumatoid arthritis. Clin Exp Immunol. 2018;194(1):1–8. https://doi.org/10.1111/cei.13188.CrossRefPubMedPubMedCentral

14.

Cici D, Corrado A, Rotondo C, Cantatore FP. Wnt signaling and biological therapy in rheumatoid arthritis and spondyloarthritis. Int J Mol Sci. 2019;20:E5552.CrossRefPubMed

15.

Szentpétery Á, Horváth Á, Gulyás K, Pethö Z, Bhattoa HP, Szántó S, et al. Effects of targeted therapies on the bone in arthritides. Autoimmun Rev. 2017;16(3):313–20. https://doi.org/10.1016/j.autrev.2017.01.014.CrossRefPubMed

16.

Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(11):1495–9. https://doi.org/10.1136/ard.2005.044198.CrossRefPubMedPubMedCentral

17.

Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(3):353–7. https://doi.org/10.1136/ard.2007.076604.CrossRefPubMed

18.

Terpos E, Fragiadaki K, Konsta M, Bratengeier C, Papatheodorou A, Sfikakis PP. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. Clin Exp Rheumatol. 2011;29:921–5.PubMed

19.

Briot K, Rouanet S, Schaeverbeke T, Etchepare F, Gaudin P, Perdriger A, et al. The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis. Joint Bone Spine. 2015;82(2):109–15. https://doi.org/10.1016/j.jbspin.2014.10.015.CrossRefPubMed

20.

Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum. 2010;62(1):33–43. https://doi.org/10.1002/art.25053.CrossRefPubMed

21.

Matuszewska A, Szechiński J. Evaluation of selected bone metabolism markers in rheumatoid arthritis patients. Adv Clin Exp Med. 2013;22(2):193–202.PubMed

22.

Sodek J, Chen J, Nagata T, Kasugai S, Todescan R Jr, Li IW, et al. Regulation of osteopontin expression in osteoblasts. Ann N Y Acad Sci. 1995;760(1 Osteopontin):223–41. https://doi.org/10.1111/j.1749-6632.1995.tb44633.x.CrossRefPubMed

23.

Si J, Wang C, Zhang D, Wang B, Zhou Y. Osteopontin in bone metabolism and bone diseases. Med Sci Monit. 2020;26:e919159.CrossRefPubMedPubMedCentral

24.

Iwadate H, Kobayashi H, Kanno T, Asano T, Saito R, Sato S, et al. Plasma osteopontin is correlated with bone resorption markers in rheumatoid arthritis patients. Int J Rheum Dis. 2014;17(1):50–6. https://doi.org/10.1111/1756-185X.12115.CrossRefPubMed

25.

Colebatch AN, Edwards CJ, Østergaard M, van der Heijde D, Balint PV, D'Agostino MA, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis. 2013;72(6):804–14. https://doi.org/10.1136/annrheumdis-2012-203158.CrossRefPubMed

26.

D'Agostino MA, Boers M, Wakefield RJ, Emery P, Conaghan PG. Is it time to revisit the role of ultrasound in rheumatoid arthritis management? Ann Rheum Dis. 2017;76(1):7–8. https://doi.org/10.1136/annrheumdis-2016-210453.CrossRefPubMed

27.

Nishino A, Kawashiri SY, Koga T, Iwamoto N, Ichinose K, Tamai M, et al. Ultrasonographic efficacy of biologic and targeted synthetic disease-modifying antirheumatic drug therapy in rheumatoid arthritis from a multicenter rheumatoid arthritis ultrasound prospective cohort in Japan. Arthritis Care Res (Hoboken). 2018;70(12):1719–26. https://doi.org/10.1002/acr.23551.CrossRef

28.

Endo Y, Koga T, Kawashiri SY, Morimoto S, Nishino A, Okamoto M, et al. Anti-citrullinated protein antibody titre as a predictor of abatacept treatment persistence in patients with rheumatoid arthritis: a prospective cohort study in Japan. Scand J Rheumatol. 2020;49(1):13–7. https://doi.org/10.1080/03009742.2019.1627411.CrossRefPubMed

29.

Endo Y, Kawashiri SY, Morimoto S, Nishino A, Okamoto M, Tsuji S, et al. Non-TNF inhibitor switchers versus TNF inhibitor cyclers from multicentre rheumatoid arthritis ultrasonography prospective cohort in Japan. Immunol Med. 2020;43(3):115–20. https://doi.org/10.1080/25785826.2020.1757920.CrossRefPubMed

30.

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24. https://doi.org/10.1002/art.1780310302.CrossRefPubMed

31.

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81. https://doi.org/10.1002/art.27584.CrossRefPubMed

32.

D'Agostino MA, Boers M, Wakefield RJ, Berner Hammer H, Vittecoq O, Filippou G, et al. Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study. RMD Open. 2016;2(1):e000237. https://doi.org/10.1136/rmdopen-2015-000237.CrossRefPubMedPubMedCentral

33.

Singh A, Gupta MK, Mishra SP. Study of correlation of level of expression of Wnt signaling pathway inhibitors sclerostin and dickkopf-1 with disease activity and severity in rheumatoid arthritis patients. Drug Discov Ther. 2019;13(1):22–7. https://doi.org/10.5582/ddt.2019.01011.CrossRefPubMed

34.

Wang SY, Liu YY, Ye H, Guo JP, Li R, Liu X, et al. Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. J Rheumatol. 2011;38(5):821–7. https://doi.org/10.3899/jrheum.100089.CrossRefPubMed

35.

Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13(2):156–63. https://doi.org/10.1038/nm1538.CrossRefPubMed

36.

Schett G, Stach C, Zwerina J, Voll R, Manger B. How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum. 2008;58(10):2936–48. https://doi.org/10.1002/art.23951.CrossRefPubMed

37.

Strunk J, Heinemann E, Neeck G, Schmidt KL, Lange U. A new approach to studying angiogenesis in rheumatoid arthritis by means of power Doppler ultrasonography and measurement of serum vascular endothelial growth factor. Rheumatology (Oxford). 2004;43(12):1480–3. https://doi.org/10.1093/rheumatology/keh380.CrossRef

38.

Paleolog EM. Angiogenesis in rheumatoid arthritis. Arthritis Res. 2002;4(Suppl 3):S81–90. https://doi.org/10.1186/ar575.CrossRefPubMedPubMedCentral

39.

Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Satoh K, Tamai M, et al. The power Doppler ultrasonography score from 24 synovial sites or 6 simplified synovial sites, including the metacarpophalangeal joints, reflects the clinical disease activity and level of serum biomarkers in patients with rheumatoid arthritis. Rheumatology (Oxford). 2011;50(5):962–5. https://doi.org/10.1093/rheumatology/keq415.CrossRef

40.

Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 2008;58(10):2958–67. https://doi.org/10.1002/art.23945.CrossRefPubMed

41.

Fassio A, Adami G, Gatti D, Orsolini G, Giollo A, Idolazzi L, et al. Inhibition of tumor necrosis factor-alpha (TNF-alpha) in patients with early rheumatoid arthritis results in acute changes of bone modulators. Int Immunopharmacol. 2019;67:487–9. https://doi.org/10.1016/j.intimp.2018.12.050.CrossRefPubMed

42.

Roser-Page S, Vikulina T, Zayzafoon M, Weitzmann MN. CTLA-4Ig-induced T cell anergy promotes Wnt-10b production and bone formation in a mouse model. Arthritis Rheumatol. 2014;66(4):990–9. https://doi.org/10.1002/art.38319.CrossRefPubMedPubMedCentral

43.

Roser-Page S, Vikulina T, Weiss D, Habib MM, Beck GR Jr, Pacifici R, et al. CTLA-4Ig (abatacept) balances bone anabolic effects of T cells and Wnt-10b with antianabolic effects of osteoblastic sclerostin. Ann N Y Acad Sci. 2018;1415(1):21–33. https://doi.org/10.1111/nyas.13643.CrossRefPubMedPubMedCentral

44.

Schett G, Redlich K, Smolen JS. The role of osteoprotegerin in arthritis. Arthritis Res Ther. 2003;5(5):239–45. https://doi.org/10.1186/ar990.CrossRefPubMedPubMedCentral

45.

van Tuyl LH, Voskuyl AE, Boers M, Geusens P, Landewé RB, Dijkmans BA, et al. Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Ann Rheum Dis. 2010;69(9):1623–8. https://doi.org/10.1136/ard.2009.121764.CrossRefPubMed

46.

Szentpetery A, McKenna MJ, Murray BF, Ng CT, Brady JJ, Morrin M, et al. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis. J Rheumatol. 2013;40(5):653–62. https://doi.org/10.3899/jrheum.120397.CrossRefPubMed

Title: Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan
Authors: Shin-ya Kawashiri
Yushiro Endo
Ayako Nishino
Momoko Okamoto
Sosuke Tsuji
Ayuko Takatani
Toshimasa Shimizu
Remi Sumiyoshi
Tomohiro Koga
Naoki Iwamoto
Kunihiro Ichinose
Mami Tamai
Hideki Nakamura
Tomoki Origuchi
Toshiyuki Aramaki
Yukitaka Ueki
Tamami Yoshitama
Nobutaka Eiraku
Naoki Matsuoka
Akitomo Okada
Keita Fujikawa
Hiroaki Hamada
Shuji Nagano
Yoshifumi Tada
Atsushi Kawakami
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Ultrasound
Abatacept
Rheumatoid Arthritis
Ultrasound
Biomarkers
Published in: BMC Musculoskeletal Disorders / Issue 1/2021
Electronic ISSN: 1471-2474
DOI: https://doi.org/10.1186/s12891-021-04392-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan

Abstract

Background

Methods

Results

Conclusion

Trial registration

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2021

Jigless knotless internal brace versus other open Achilles tendon repairs using a progressive rehabilitation protocol: a biomechanical study

Cross-cultural adaptation and validation of the German Central Sensitization Inventory (CSI-GE)

Is coracoclavicular reconstruction necessary in hook plate fixation for acute unstable acromioclavicular dislocation?

Re-evaluating the necessity of routine laboratory tests after high tibial osteotomy surgery

Assessing the risk of rapid radiographic progression in Hungarian rheumatoid arthritis patients

A novel vertebral trench technique (VTT) involving transforaminal endoscopic lumbar foraminotomy (TELF) for very highly up-migrated lumbar disc herniation above L5